

Ref.: NLL/CS/2025- 537

August 11, 2025

To,

1. National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051

Symbol: NECLIFE

2. BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001

Scrip Code: 532649

Sub: Regulation 30 of the Securities and Exchange of Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and as amended upto date.

Dear Sir/ Madam,

Please be informed that the State Service of Ukraine on Medicines and Drugs Control (SMDC) has granted the **Certification of Good Manufacturing Practices for Medicinal products** for Unit VI of Nectar Lifesciences Limited ("Company"), located at Village Bhatolikalan, Adjoining Jharmajri, E.P.I.P., P.O. Barotiwala, Tehsil Baddi, District Solan, Himachal Pradesh, 174103, India, as referred to in the Guide: 42-4.0:2020 for Good practices in the manufacture and quality control of the Pharmaceutical Inspection Convention/Cooperation Scheme (PIC/S), EU Directives, and World Health Organization recommendations in respect of products to be sold or distributed within the country of origin or to be exported from State Service of Ukraine on Medicines and Drugs Control.

This Certification is valid for till April 18, 2026.

The shareholders of Company have already approved the slump sale of Unit VI, which has been disclosed vide letter no. NLL/CS/2025- 533 dated August 04, 2025 read with letter no. NLL/CS/2025- 514 dated July 07, 2025

Kindly take the same on record.

Thanking you,

Yours faithfully,

For **Nectar Lifesciences Limited**

(Sanjaymohan Singh Rawat)

Company Secretary & Compliance Officer